Lorven Biologics Germany is a Contract Development and Manufacturing Organization (CDMO) - a company that offers comprehensive services, ranging from drug development to drug manufacturing to other companies in the pharmaceutical industry on a contract basis. Outsourcing these funcions allows the companies to improve scalability and focus on other important areas like drug discovery and commercialisation. Findings from a 2022 analysis published by Ernst & Young titled " Contract Development and Manufacturing Organizations (CDMOs) are leading innovation for pharmaceutical partners" (read the study
here) suggest a continued consolidation trend in the CDMO market and reveal companies' particular investment focus on technology and capabilities. In particular, the emergence of new technologies offers potential to revolutionise therapies and supply chains. These trends are expected to continue in the coming years.

The emergence of novel modalities (such as cell therapies, gene therapies or mRNA therapies) and innovative vaccines over the last decade has required significant investment in new, additional production capacity for viral vectors, cell manipulation, as well as nucleic acids and lipid-based formulations. As a well-positioned CDMO, we are able to flexibly adapt production lines to meet the increasing demand for smaller, more diverse projects. New partnerships can thus emerge, enabling us to drive rapid growth in capacity and capability and help the industry succeed in the most forward-looking and sustainable areas.

In modern science, synthetic biology and biotechnology have great potential to shape the industrialization of biology that will drive rapid development of novel microbial manufacturing platforms.

Our in-house developed, proprietary, and innovative bacterial and yeast  expression platforms, in conjunction with synthetic biology tools, offer unique commercial potential  in the development of high value complex bio-products  through rational design of heterologous pathways into microbes

Advantages:

Our Synthetic biology and strain engineering platforms for development of high value natural products have great advantages over conventional production practices in-terms of,

• Environment-friendly process (control in pollution by avoiding toxic solvents & chemicals in purification/extraction process, reduction in carbon foot print)
• Significant increase in product yields
• Product Purity
• Reduction in turnaround time to reach the market
• Remarkably reduced production cost

Bio-process development

Bio-process development is the process of designing, constructing, and optimizing industrial-scale processes for the manufacture of biologics (products derived from living organisms). It involves integration of molecular biology, biochemistry, bioprocess engineering, and other disciplines to create a reproducible and cost-effective process for the production of biologics. It includes the development of upstream and downstream processes, as well as process analytical technology, to ensure that the final product meets the desired quality standards.

The importance of bio-process development

1. Improved Efficiency of Production: Efficiency in the production of bioproducts and other related processes could be improved, allowing increased production and cost savings.
2. Enhanced Quality Control: Enhanced quality control measures reduce the risk of product defects and improve the overall quality of the product.
3. Increased Productivity: Increased productivity is achieved as a result of improved process control, enhanced production monitoring, and automated workflow.
4. Reduced Waste: The amount of waste generated during the production process is significantly reduced, which can lead to cost savings.
5. Increased Safety: Safe operation of production processes is ensured and the risk of accidents and injuries is reduced.